Haw Par's (SGX:H02) profit declined 5.5% in the second half of 2024 to SG$106.3 million from SG$112.4 million a year earlier, according to a filing with the Singapore Exchange on Friday.
Earnings per share decreased to SG$0.48 compared with SG$0.508 in the comparable period.
Revenue was up 4.8% year over year to SG$126.7 million from SG$120.9 million year over year, driven by higher sales from the healthcare division.
Shares of the pharmaceutical company were up over 7% in recent trading.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。